Table 2.
Operative, pathologic, and outcome variables in R and BR PDAC patients who received NAT and underwent curative-intent pancreaticoduodenectomy.
| Variable | Overall cohort (n = 273) |
Recurrence ≤6 months (n = 64) |
Recurrence >6 month/no recurrence (n = 209) |
P-value |
|---|---|---|---|---|
| Robotic approach | 105 (39) | 27 (42) | 78 (37) | 0.484 |
| EBL, mL | 300 (175–300) | 400 (300–750) | 300 (150–550) | 0.007 |
| T stage | ||||
| 0 | 4 (1.5) | 0 (0) | 4 (1.9) | |
| 1 | 94 (34) | 21 (33) | 73 (35) | |
| 2 | 150 (55) | 33 (52) | 117 (60) | 0.217 |
| 3 | 24 (9) | 10 (16) | 14 (7) | |
| 4 | 1 (0.4) | 0 (0) | 1 (0.5) | |
| Pathologic tumor size, cm | 2.5 (2–3.3) | 3 (2–3.5) | 2.5 (2–3) | 0.106 |
| N stage | ||||
| 0 | 96 (35) | 19 (30) | 77 (37) | |
| 1 | 101 (37) | 25 (39) | 76 (36) | 0.544 |
| 2 | 76 (28) | 20 (31) | 56 (27) | |
| Total number of LN harvested | 27 (20–36) | 26 (18–35) | 28 (20–37) | 0.307 |
| Number of positive LN | 1 (0–4) | 2 (0–5) | 1 (0–4) | 0.177 |
| Ratio of positive LN | 0.05 (0–0.14) | 0.08 (0–0.21) | 0.04 (0–0.14) | 0.058 |
| LVI | 186 (70) | 51 (81) | 135 (67) | 0.032 |
| PNI | 222 (82) | 56 (90) | 166 (80) | 0.057 |
| Positive margins | 130 (48) | 35 (55) | 95 (46) | 0.196 |
| Response to NAT | ||||
| None/absent | 50 (22) | 14 (28) | 36 (20) | |
| Partial | 167 (73) | 36 (22) | 131 (74) | 0.495 |
| Near complete | 7 (3) | 1 (2.0) | 6 (3) | |
| Complete | 4 (1.8) | 0 (0) | 4 (2.3) | |
| 30-day mortality | 4 (1.5) | 4 (6) | 0 (0) | 0.003 |
| 90-day mortality | 10 (4) | 10 (16) | 0 (0) | <0.001 |
| Clavien-Dindo score ≥3 | 73 (26.7) | 27 (42) | 46 (22) | 0.001 |
| Adjuvant chemotherapy | 201 (75.6) | 31 (51) | 170 (83) | <0.001 |
| Gemcitabine based | 166 (83) | 23 (74) | 143 (85) | |
| 5-fluorouracil based | 27 (13.5) | 6 (19) | 21 (12) | 0.239 |
| Crossover | 7 (3.5) | 2 (6.5) | 5 (3.0) | |
| Number of Adjuvant cycles | 4 (3–6) | 3 (2–4) | 5 (4–6) | <0.001 |
| Total number of cycles (NAT + adjuvant) |
7 (4–9) | 4 (3–6) | 8 (5–9) | <0.001 |
| Recurrence | ||||
| Local recurrence | 65 (24) | 8 (16) | 57 (39) | |
| Carcinomatosis | 8 (3) | 3 (6) | 5 (34) | 0.004 |
| Single distant organ | 80 (30) | 22 (43) | 58 (40) | |
| Multiple sites | 43 (16) | 18 (35) | 25 (17) | |
Variables are presented as medians (interquartile range), raw numbers (percentage). EBL: estimated blood loss, LN: lymph nodes, LVI: lympho-vascular invasion, PNI: peri-neural invasion, NAT: neoadjuvant chemotherapy